An observational study in Acute Pancreatitis, sponsored by Asian Institute of Gastroenterology, India. Recruiting at 1 site in India. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Asian Institute of Gastroenterology, India · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Pancreatitis with a site in India — 7 open to participants now, 7 under way, 2 of them phase 3. Pancreatitis · India.
Among the 18 studies in Pancreatitis with a site in India, this one is one of 2 that started in 2025, is one of 5 observational ones, and was the 16th registered.
558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.
Browse Pancreatitis studies →7 of the 18 studies in Pancreatitis with a site in India are open now. Recruiting first, the newest first:
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–60
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–75
Panafina, Inc. · Sites in India, United States
Ages 18–85
Moti Lal Nehru Medical College · Sites in India
Ages 18–65
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–70
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 5
First in 2003; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 200 across 193 observational studies indexed under Pancreatitis.
Median enrollment 140 across the 13 interventional studies, 246 across the 5 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 18 have an industry lead sponsor. The 9 most frequent:
Asian Institute of Gastroenterology, India is the lead sponsor of 135 studies on the registry; 59 are open to participants now.
Asian Institute of Gastroenterology, India has 3 studies filed under Pancreatitis — fewer than ten, so there is no comparison to draw.
4 of the studies in Pancreatitis with a site in India that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05252754Phase 3Johns Hopkins UniversityRectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis | 2026-12 |
| NCT07441824Phase 3Asian Institute of Gastroenterology, IndiaPancreatic Enzyme Replacement in Acute Necrotizing Pancreatitis | 2027-06 |
| NCT06080789Panafina, Inc.A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis | 2026-12 |
| NCT07395778Post Graduate Institute of Medical Education and Research, ChandigarhNasojejunal Feeding Versus Oral Feeding Following Endoscopic Drainage of Walled Off Pancreatic Necrosis | 2026-12-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 18 studies in Pancreatitis with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Acute pancreatitis (AP) is a common medical condition characterized by inflammation of the pancreas, affecting a significant portion of the population. With approximately one-third of patients experiencing notable morbidity due to local or systemic complications, the severity of the disease is underscored by the presence of acute peripancreatic fluid collections, acute necrotic collections, pseudocysts, and walled-off necrosis1. Notably, vascular complications, such as splanchnic vein thrombosis, further contribute to the increased morbidity and mortality associated with acute pancreatitis2. Splanchnic vein thrombosis encompasses thromboses in the splenic (SpVT), portal (PVT), and superior mesenteric veins (SMVT), either individually or in combination3. These complications are often incidentally discovered during imaging procedures conducted to assess potential complications4. Despite most cases being asymptomatic, fatal complications, including bowel ischemia, liver failure, portal hypertension, and life-threatening bleeding, have been documented, with the risk of splanchnic vein thrombosis escalating with the severity of pancreatitis
Acute pancreatitis (AP) is a common medical condition characterized by inflammation of the pancreas, affecting a significant portion of the population. With approximately one-third of patients experiencing notable morbidity due to local or systemic complications, the severity of the disease is underscored by the presence of acute peripancreatic fluid collections, acute necrotic collections, pseudocysts, and walled-off necrosis1. Notably, vascular complications, such as splanchnic vein thrombosis, further contribute to the increased morbidity and mortality associated with acute pancreatitis2. Splanchnic vein thrombosis encompasses thromboses in the splenic (SpVT), portal (PVT), and superior mesenteric veins (SMVT), either individually or in combination3. These complications are often incidentally discovered during imaging procedures conducted to assess potential complications4. Despite most cases being asymptomatic, fatal complications, including bowel ischemia, liver failure, portal hypertension, and life-threatening bleeding, have been documented, with the risk of splanchnic vein thrombosis escalating with the severity of pancreatitis.
The intricate relationship between the pancreas and large mesenteric vessels, coupled with systemic inflammatory responses, hypovolemia, fluid shifts, and prothrombotic states, contributes to the development of splanchnic vein thrombosis in acute pancreatitis5. Early detection of these thrombotic events becomes imperative to mitigate long-term sequelae such as portal hypertension and chronic mesenteric ischemia6. Despite the critical importance of identifying splanchnic vein thrombosis in acute pancreatitis, there is a notable absence of standardized recommendations for initiating anticoagulation treatment in these cases5. The decision-making process is further complicated by the potential risk of bleeding associated with other vascular complications, such as bleeding into pseudocysts or pseudo-aneurysmal bleeds7. As a result, there is a pressing need for more comprehensive studies that delve into the risk factors, pathogenesis, therapeutic impacts, and outcome predictors associated with splanchnic vein thrombosis in the context of acute pancreatitis. These investigations will not only enhance our understanding of the condition but also inform the development of evidence-based guidelines for the management of splanchnic vein thrombosis in individuals with acute pancreatitis.
All in-patients with acute pancreatitis, getting admitted from emergency or OPD will be enrolled. Only when a study subject has given informed consent, clinical data will be recorded
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Primary outcome
Detection of thrombus in splenic, superior mesenteric or portal vein.
Time frame: 1 year
Secondary Outcome
Correlation of splanchnic venous thrombosis with severity of acute pancreatitis.
Time frame: 1 year
Secondary Outcome
Incidence of infected pancreatic necrosis/ peri-pancreatic fluid collections in patients with acute pancreatitis having SVT.
Time frame: 1 year
Secondary Outcome
Effect of drainage of peripancreatic fluid collections/ necrotic collections on status of thrombosis.
Time frame: 1 year
Secondary Outcome
Vessel recanalization on follow-up at 6 months
Time frame: 6 months
Started Feb 2025 (actual). Primary completion is estimated for Feb 2026, 12 months after the start.
Of 82 non-industry observational studies under Pancreatitis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 133. This study's planned 12 months is below that.
Counting every sponsor, half of 86 studies reached it within 50 months; a quarter within 21 and three quarters within 133.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Asian Institute of Gastroenterology, India →